Zoetis Inc. Annual Report, Year Ended Dec 31, 2018

Zoetis Inc. reported strong financial performance for the fiscal year ended December 31, 2018, with total revenue reaching $5.825 billion, a 10% increase year-over-year. This growth was driven by a balanced performance across both its U.S. and International segments, with revenues of $2.877 billion and $2.890 billion, respectively. The company saw robust growth in its companion animal segment, up 17% to $2.613 billion, largely attributed to its key dermatology products and the strategic acquisition of Abaxis. The livestock segment also contributed positively, growing 4% to $3.154 billion, benefiting from demand for alternatives to antibiotic medicated feed additives and new product introductions. Net income attributable to Zoetis was $1.428 billion, a significant 65% increase from the previous year, bolstered by strong revenue growth and improved operational efficiencies. The company also benefited from a lower effective tax rate in 2018, following the enactment of the Tax Cuts and Jobs Act, which reduced the U.S. federal corporate tax rate. Zoetis continued its commitment to shareholder returns through share repurchases, authorizing an additional $2.0 billion, indicating confidence in its ongoing business strategy and future prospects.